Launch your Graphy
There are no items in your cart
Add More
Add More
| Item Details | Price | ||
|---|---|---|---|
Integrating Whole-Exome Sequencing with Clinical and Histopathological Endpoints in Chemoprevention Studies
access_time 2026-01-03T07:21:16.852Z face Shruti Joshi
Integrating Whole-Exome Sequencing with Clinical and Histopathological Endpoints in Chemoprevention Studies SwaLife Biotech 03.01.26 From Molecular Signals to Meaningful Prevention Outcomes Chemoprevention research is undergoing a major transformation. Traditional trials often rely on clinical impro...
Mutation Signatures and Genome Protection
access_time 2026-01-02T11:43:13.638Z face Shruti Joshi
Mutation Signatures and Genome Protection SwaLife Biotech 2.1.26 Applications of Whole-Exome Sequencing (WES) in Chemoprevention Trials Cancer does not emerge overnight. Long before clinical detection, genomes accumulate mutations driven by carcinogen exposure, oxidative stress, chronic inflammation...
Clonal Evolution and Genomic Stability as Endpoints of Chemoprevention
access_time 2025-12-31T12:08:15.58Z face Shruti Joshi
Clonal Evolution and Genomic Stability as Endpoints of Chemoprevention SwaLife Biotech 31.12.25 Evidence from Whole-Exome Sequencing Studies Cancer prevention has traditionally been measured by a single, blunt outcome: whether cancer eventually appears or not. Yet advances in cancer genomics particu...
Whole-Exome Sequencing in Cancer Chemoprevention
access_time 2025-12-31T07:41:17.728Z face Shruti Joshi
Whole-Exome Sequencing in Cancer Chemoprevention SwaLife Biotech 31.12.25 Tracking Mutational Trajectories in High-Risk Populations Cancer does not appear overnight. Long before a tumor becomes clinically visible, cells quietly accumulate genetic alterations that reshape their behavior and destiny. ...
RNA-seq–Driven Discovery of Chemoprevention Biomarkers in Animal Models
access_time 2025-12-30T06:45:26.348Z face Shruti Joshi
RNA-seq–Driven Discovery of Chemoprevention Biomarkers in Animal Models SwaLife Biotech 30.12.25 From Bench to Biomarkers One of the biggest challenges in cancer chemoprevention is not identifying promising compounds but proving that they are to justify long, expensive clinical trials. Unlike therap...